We show here that acute administration of gefitinib inhibits EGFR signalling while also activating the IGF1R pathway in adenomas developing in the Apcmin/+ mouse, an in vivo physiologically relevant model of intestinal tumourigenesis. The gene discussed is EGFR; the disease is adenoma.